GLP-3 RTGLP-3R · 10MG / 20MG / 30MG LYOPHILIZED VIALS

GLP-3 RT

GLP-3 RT is a lyophilized research peptide in the Rogue Compounds GLP Collection, offered in 10mg, 20mg and 30mg vials. It belongs to the newest class of incretin-receptor research peptides: multi-receptor agonists designed to act at three related receptors at once, the GLP-1 receptor, the GIP receptor and the glucagon receptor.

Product Specifications

• Product: GLP-3 RT
• Amount: 10mg / 20mg / 30mg
• Form: Lyophilized powder
• Purity: Third-party tested by an ISO 17025 U.S. laboratory. See the batch Certificate of Analysis (COA) on this page.
• Storage: Keep sealed and refrigerated at 2–8°C (36–46°F), protected from light.
• Ships from: United States, 2-day UPS

Compound identifiers are provided on the batch Certificate of Analysis.

The receptor biology

All three targets are class B G protein-coupled receptors that respond to peptide hormones and signal mainly through G_s and cAMP:

• GLP-1 receptor: activated by glucagon-like peptide-1, an incretin hormone released from intestinal L-cells. It is expressed in pancreatic islets, the brain, heart, gut and other tissues, and is one of the most studied receptors in metabolic research.
• GIP receptor: activated by glucose-dependent insulinotropic polypeptide, the other major incretin, released from intestinal K-cells. Its role in fat tissue and the brain is an active area of study.
• Glucagon receptor: activated by glucagon from pancreatic alpha cells and expressed mainly in the liver, where it is central to studies of hepatic glucose and lipid metabolism and energy expenditure.

What researchers study

Single-receptor agonists came first, followed by dual GLP-1/GIP agonists. Triple-receptor peptides let laboratories ask how combined signaling at all three receptors compares with activating one or two: receptor selectivity and potency, cAMP and downstream signaling in cell systems, and how the balance between the three pathways shapes metabolic readouts in preclinical models. GLP-3 RT is supplied for that kind of in-vitro and analytical work.

Regulatory status

GLP-3 RT is not an FDA-approved drug and is not sold for human or veterinary use. It is a research reagent only.

Quality & Documentation

Every batch of GLP-3 RT is made in small runs for Rogue Compounds and tested by an independent U.S. laboratory for identity (mass spectrometry) and purity (HPLC). Each vial is labeled with its batch number and a QR code that opens the testing lab’s own report for that batch. The same batch Certificate of Analysis is posted on this page and in our COA Library, so you can check one against the other.

Background reading on the receptors

• Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819-837. PMID 23684623
• Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27:740-756. PMID 29617641
• Müller TD, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. PMID 31767182
• Finan B, Capozzi ME, Campbell JE. Repositioning glucagon action in the physiology and pharmacology of diabetes. Diabetes. 2020;69(4):532-541. PMID 31178432
• Campbell JE, Drucker DJ. Therapeutic targeting of the GIP receptor: revisiting the controversies. Diabetes. 2025;74(8):1320-1325. PMID 40521880

Research Use Only

This product is sold strictly as a research chemical for in-vitro laboratory and analytical use by qualified professionals. It is not a drug, dietary supplement, food, or cosmetic, and it is not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Rogue Compounds does not provide dosing, preparation, or usage instructions. The literature on this page is listed for scientific background only and does not describe this product or any use of it.